Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion

DRUG3 trials

Sponsors

CHU Gabriel-Montpied, Centre Hospitalier Regional Universitaire De Tours, Universitair Ziekenhuis Antwerpen

Conditions

Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:Patients in ICU with risks of Acute Respiratory Distress SyndromeSedation in healthy children

Phase 2

The use of intranasal dexmedetomidine for pediatric sedation in non-invasive radiological procedures (CTMS 004321) Assessing the efficacy and safety profile of intranasal dexmedetomidine for procedural sedation in radiological procedures in children with a prospective exploratory interventional monocentric study in a tertiary center in Antwerp (Belgium)

Not yet recruitingCTIS2025-522778-34-00

Universitair Ziekenhuis AntwerpenSedation in healthy children

Target: 100Updated: 2025-11-07

Phase 3

Randomized Clinical Trial of Inhaled Sedation with Sevoflurane in Critically Ill Patients at Risk of Developing the Acute Respiratory Distress Syndrome

RecruitingCTIS2024-517670-15-00

CHU Gabriel-MontpiedPatients in ICU with risks of Acute Respiratory Distress Syndrome

Start: 2023-07-24Target: 80Updated: 2025-11-10

Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial

Not yet recruitingCTIS2025-521039-35-00

Centre Hospitalier Regional Universitaire De ToursImpact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

Target: 266Updated: 2025-10-29